The Green Baron Report

Tuesday, June 29, 2010

New “Stock Pick”

BioDrain Medical, Inc. (BB: BIOR)

New Green Baron Webcast Interview with CEO Kevin Davidson Now Available

BioDrain’s Fully Automated, Patented, Recently FDA-Cleared Product Improves Safety in Operating Rooms, Reduces Costs, Improves Efficiency, and is Eco-Friendly

Click to View New BIOR “Stock Pick” Report

BIOR Report

After the close of trading yesterday, The Green Baron Report released its 89^th “Stock Pick” since inception. Our most recent four “Stock Picks” have rallied anywhere from 25% to 86% within weeks after release of our profiles, and this new “Stock Pick” has the ability to quadruple in price quickly. For example back in April, BIOR shot up from about .20 per share to hit .90 per share in about a week.

Please take time today to listen to our new CEO webcast interview with Kevin Davidson, and review our new report on the Company. General market weakness over the past few months has created a wonderful buying opportunity in BIOR stock at just .20 per share. Just prior to going public, accredited investors paid .50 per share that included a warrant at .65 per share. We believe the current price is an absolute bargain and will not last.

Again, here are some reasons we like BioDrain Medical:

1. FDA Cleared and Patented – BioDrain’s Streamway™ System has already been cleared by the FDA and the System is ready for scaled up manufacturing now. There is no waiting on the FDA to approve the product. The Company has also received patents from both the European Patent Office and the US Patent & Trademark Office.

2. Reduced Costs to Users – The Streamway System cuts expenses by eliminating costly canisters, their handling and disposal costs including related hazardous material disposal fees. Since the System also delivers uninterrupted, continual performance, use of the System increases operative efficiency and decreases time for set-up and clean up.

3. Improved Safety – Since the System virtually eliminates surgical fluid handling, the reduced potential exposure to germs, viruses and diseases vastly improves safety for healthcare staff.

4. Considered Best on Market – The features and benefits of its Streamway™ System make it the best product available among its competition and peers. BioDrain has both US and European patents with claims relating to the constant and continuous suction of surgical fluid, and its visualization capabilities that are desired by doctors as they can see the color of the surgical fluid removed. Additionally, unlimited volumes of surgical fluid can be collected, measured, and disposed of by use of the System without interruption.

5. Razor / Razor Blade Model - BioDrain Medical will sell the wall-mounted Streamway System, as well as a procedure filter and proprietary cleaning fluid that will be utilized to clean the System after each surgical procedure. This “razor/razor blade” business model will allow the Company to obtain an annuity-type of revenue stream from the placement of each System.

6. Government Mandates Addressed - BioDrain Medical’s System address issues raised by government and institutional mandates and guidelines. OSHA, EPA, DOT and other agencies have addressed the appropriate, recommended handling of infectious fluids by hospitals and institutions. Separately, hospitals and state and local governments also have addressed the need for safer handling of these fluids. Such mandates include recommendations for the use of automated controls. The BioDrain Medical Streamway System fully automates the collection, measurement, and disposal of surgical fluids.

7. Environmental Benefits – Currently, management estimates that approximately 50 million bloody, potentially disease filled, fluid canisters go to landfills annually in the United States alone. With BioDrain's System, that number could be zero.

8. Attractive Valuation – The Green Baron Report believes BioDrain should realistically turn profitable in 2011 with an operating profit of nearly $2 million, and over $10 million for 2012. After the stock touched $.90 per share in April, BIOR is now near its year low with a market cap of less than $3 million. The Company’s most recent private placement to accredited investors was much higher at $.50 per share with a $.65 warrant.

About BioDrain Medical, Inc.

BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid management system that virtually eliminates Operating Room workers' exposure to blood, irrigation fluid and the related germs, viruses and diseases that are potentially found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's Streamway™ System fully automates the collection, measurement and disposal of surgical fluids resulting in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving the Occupational State and Health Association (OSHA) and other regulatory compliance, and 3) improving the efficiency of the Operating Room (and thereby making surgeries more profitable).

BioDrain's Streamway System is eco-friendly as it contributes to the cleaning up the environment. Currently ~ 50 million bloody, potentially disease filled, canisters go to landfills annually in the United States. ~50 million canisters tainted with surgical fluids that can remain in the landfill for years to come. With BioDrain's System, that number of canisters could be zero. BioDrain Medical, Inc. makes the Operating Room and our planet safer, cleaner, better. BioDrain products are currently being represented by ~ 30 independent professional sales representatives that cater to the needs of hospitals across the country. Learn more about BioDrain Medical, Inc. by visiting www.biodrainmedical.com.